At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsHigh earnings quality
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.38%Below 5Y avg (0.49%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.76BCNY563.51M · vs all stocks (USD)
Revenue (TTM)
388.64MCNY58.29M · vs all stocks (USD)
Profit Margin
-45.51%Beta
0.2430xvs all stocks
52-Week Change
-35.81%vs all stocks
Market Capitalization
3.76BCNY563.51M · vs all stocks (USD)
Enterprise Value
2.32BCNY347.67M · vs all stocks (USD)
Price to Sales (TTM)
9.77xPrice to Book (MRQ)
1.18xEnterprise to Revenue
5.96xEnterprise to EBITDA
116.07xGross Margin
67.58%Profit Margin
-45.51%Operating Margin
-12.89%Return on Assets (TTM)
-0.45%Return on Equity (TTM)
-5.52%Revenue (TTM)
388.64MCNY58.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.7990CNYUpdated Oct 21, 2026Quarterly Revenue Growth
-13.40%Gross Profit (TTM)
252.25MCNY37.84M · vs all stocks (USD)
EBITDA (TTM)
68.19MCNY10.23M · vs all stocks (USD)
Net Income (TTM)
-176.89MCNY-26.53M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.43%Operating Cash Flow (TTM)
9.14MCNY1.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-59.80MCNY-8.97M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0300CNYUpdated Oct 21, 2026Trailing Annual Dividend Yield
0.38%vs all stocks
5-Year Average Dividend Yield
0.49%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
21.47MCNYFY2025 · Dec 31, 2025Revenue
404.72MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
141.19MCNYFY2025 · Dec 31, 2025Gross Profit
263.53MCNYFY2025 · Dec 31, 2025Operating Income
-8.87MCNY-1.33M · vs all stocks (USD)
Pre-tax Income
12.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.51MCNYFY2025 · Dec 31, 2025Net Income
7.79MCNYFY2025 · Dec 31, 2025EBIT
12.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
68.19MCNYFY2025 · Dec 31, 2025Research & Development
69.51MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
152.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
454.54KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
485.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
485.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.79MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
6.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
3.45MCNYFY2025 · Dec 31, 2025Free Cash Flow
-96.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.82MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
100.92KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.96MCNYFY2025 · Dec 31, 2025Capital Expenditures
-100.10MCNYFY2025 · Dec 31, 2025Sale of Investments
91.45MCNYFY2025 · Dec 31, 2025Other Investing Activity
-37.07MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-45.73MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
19.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-250.89KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
19.74MCNYFY2025 · Dec 31, 2025Shares Outstanding
481.67MSharesUpdated Oct 21, 2026Float Shares
210.95MSharesUpdated Oct 21, 2026% Held by Insiders
57.61%vs all stocks
% Held by Institutions
0.57%vs all stocks
Total Cash (MRQ)
1.47BCNY220.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.06CNYUpdated Oct 21, 2026Total Debt (MRQ)
14.26MCNY2.14M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0044xCurrent Ratio (MRQ)
21.23xBook Value per Share (MRQ)
6.67CNYUpdated Oct 21, 2026Total Assets
3.57BCNY535.22M · vs all stocks (USD)
Total Current Assets
1.69BCNYFY2025 · Dec 31, 2025Total Liabilities
175.95MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
83.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
92.30MCNYFY2025 · Dec 31, 2025Cash
61.58MCNYFY2025 · Dec 31, 2025Cash Equivalents
26.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.13MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.47BCNYFY2025 · Dec 31, 2025Accounts Receivable
42.40MCNYFY2025 · Dec 31, 2025Inventory
68.85MCNYFY2025 · Dec 31, 2025Accounts Payable
22.63MCNYFY2025 · Dec 31, 2025Short-term Debt
19.86MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.03MCNYFY2025 · Dec 31, 2025Common Stock (Book)
481.67MCNYFY2025 · Dec 31, 2025Retained Earnings
1.80BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.39BCNY508.83M · vs all stocks (USD)
52-Week Low
7.60CNYUpdated Oct 21, 202652-Week High
13.80CNYUpdated Oct 21, 202652-Week Change
-35.81%vs all stocks
Beta
0.2430xvs all stocks
50-Day MA
8.77CNYUpdated Oct 21, 2026200-Day MA
9.95CNYUpdated Oct 21, 2026Avg 10-Day Volume
4.11MSharesUpdated Oct 21, 2026Avg 30-Day Volume
4.24MSharesUpdated Oct 21, 2026Diluted EPS (TTM)
-0.3700CNYUpdated Oct 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.68Profit Margin: -0.46
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.64
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Puma Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anteris Technologies Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule